Top Menu

Author Archive | Bob Ehrlich

New Study Wants More FDA DTC Explanations

New Study Wants More FDA DTC Explanations “The authors feel consumers misunderstand what FDA approval means.” -Bob Ehrlich Two physician researchers, Drs. Schwartz and Woloshin, have studied and published on DTC for years. They have generally been critical of drug industry communications. In their latest study published 9/12/2011 in the journal “Archives of Internal Medicine”, […]

Continue Reading

DTC Digital Frustration

“Drug company management is in a defensive posture.” -Bob Ehrlich I just returned from our annual digital DTC conference in New Jersey. I can describe the general sentiment as one of frustration. That is, frustration with FDA and their glacial movement on guidance, frustration with the pharma industry on their reluctance to take risks, and […]

Continue Reading

A Lapse in Communication

A Lapse in Communication “Doctors and patients are not properly communicating.” -Bob Ehrlich A rather disturbing survey done by Consumer Reports shows Americans are increasingly skipping their medications, cutting doses, and failing to fill a prescription entirely. That number stands at 48% of those surveyed, up 9 points from 2010. The problem is partly the […]

Continue Reading

The Future of Big Pharma

There are many reasons one can cite to predict big trouble for the drug companies in the next decade and beyond. The most significant is cost control and the expectation that government and private payers will squeeze drug company margins through price controls and less patent protection. Second is the trend towards regulatory conservatism requiring […]

Continue Reading